Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,402
Employees1,402
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,402
Employees1,402

IONS Key Statistics

Market cap
13.42B
Market cap13.42B
Price-Earnings ratio
-37.27
Price-Earnings ratio-37.27
Dividend yield
Dividend yield
Average volume
2.23M
Average volume2.23M
High today
$82.63
High today$82.63
Low today
$78.74
Low today$78.74
Open price
$78.74
Open price$78.74
Volume
3.71M
Volume3.71M
52 Week high
$86.74
52 Week high$86.74
52 Week low
$39.37
52 Week low$39.37

Stock Snapshot

As of today, Ionis Pharmaceuticals(IONS) shares are valued at $81.18. The company's market cap stands at 13.42B, with a P/E ratio of -37.27.

During the trading session on 2026-06-28, Ionis Pharmaceuticals(IONS) shares reached a daily high of $82.63 and a low of $78.74. At a current price of $81.18, the stock is +3.1% higher than the low and still -1.8% under the high.

Trading activity shows a volume of 3.71M, compared to an average daily volume of 2.23M.

The stock's 52-week range extends from a low of $39.37 to a high of $86.74.

The stock's 52-week range extends from a low of $39.37 to a high of $86.74.

IONS News

Simply Wall St 4h
Ionis Wins Tryngolza Approval And Recordati Deal For Zilganersen

Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA approval for Tryngolza (olezarsen) as the first treatment to reduce triglycerides and the risk of acute pancr...

Ionis Wins Tryngolza Approval And Recordati Deal For Zilganersen
Benzinga 3d
Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk

• Ionis Pharmaceuticals stock is moving in positive territory. Why are IONS shares climbing? The company also struck a global licensing agreement with Italy-ba...

Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk
TipRanks 3d
Ionis Buy Rating Reiterated as Tryngolza Launch Underpins Multibillion-Dollar Opportunity and Unchanged $110 Price Target

Analyst Gary Nachman of Canaccord Genuity maintained a Buy rating on Ionis Pharmaceuticals, retaining the price target of $110.00. Unlock powerful investing to...

Analyst ratings

85%

of 27 ratings
Buy
85.2%
Hold
14.8%
Sell
0%

More IONS News

TipRanks 3d
Ionis Pharmaceuticals price target raised to $130 from $125 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $130 from $125 and keeps a Buy rating on the shares following the FDA approval...

TipRanks 3d
Ionis Pharmaceuticals price target raised to $75 from $74 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $75 from $74 and keeps a Neutral rating on the shares. The firm cites the FDA ha...

Simply Wall St 6d
Ionis Pharmaceuticals Stock Could Be 26.6% Undervalued After New Olezarsen Data

Ionis Pharmaceuticals (IONS) recently shared new long-term data on its RNA therapy olezarsen for severe hypertriglyceridemia, highlighting sustained effects on...

Ionis Pharmaceuticals Stock Could Be 26.6% Undervalued After New Olezarsen Data

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.